title: Management of the contralateral testis in patients with testicular germ cell cancer.
abstract: Patients with testicular germ cell tumours (TGCT) are at increased risk of developing a tumour in the contralateral testis. Such a tumour may be preceded by carcinoma in situ (CIS), which is more common in patients with infertility, atrophic testis or a history of cryptorchism. Of 1219 patients with TGCT seen at the Royal Marsden Hospital between 1962 and 1984 in whom the contralateral testis was managed by surveillance, 38 (3.1%) developed a second tumour and 8 died of germ cell tumours. Seventeen of 26 assessable patients (65%) exhibited at least one of the known aetiological risk factors for carcinoma in situ. Diagnosis of carcinoma in situ may lead to more appropriate management of the contralateral testis.
authors.affiliation: Testicular Tumour Unit, Royal Marsden Hospital, Institute of Cancer Research, Sutton.
authors.forename: M V
authors.initials: MV
authors.lastname: Fordham
authors.forename: M D
authors.initials: MD
authors.lastname: Mason
authors.forename: C
authors.initials: C
authors.lastname: Blackmore
authors.forename: W F
authors.initials: WF
authors.lastname: Hendry
authors.forename: A
authors.initials: A
authors.lastname: Horwich
mesh_terms: D002278:Carcinoma in Situ / Q000473:pathology; D006801:Humans; D008297:Male; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis* / Q000473:pathology; D009919:Orchiectomy; D012307:Risk Factors; D013724:Teratoma / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D013736:Testicular Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000601:surgery; D013737:Testis / Q000473:pathology; D013739:Testosterone / Q000627:therapeutic use
chemical_list: D013739:Testosterone